Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape von Emens, Leisha A, Ascierto, Paolo A, Darcy, Phillip K, Demaria, Sandra, Eggermont, Alexander M.M, Redmond, William L, Seliger, Barbara, Marincola, Francesco M

Volltext

The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment von Farhad, Mohammad, Rolig, Annah S., Redmond, William L.

Volltext

Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers von Sun, Zhaoyu, Nyberg, Richard, Wu, Yaping, Bernard, Brady, Redmond, William L

Volltext

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal von Linch, Stefanie N, McNamara, Michael J, Redmond, William L

Volltext

Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer von Sanchez, Katherine, Kim, Isaac, Chun, Brie, Pucilowska, Joanna, Redmond, William L, Urba, Walter J, Martel, Maritza, Wu, Yaping, Campbell, Mary, Sun, Zhaoyu, Grunkemeier, Gary, Chang, Shu Ching, Bernard, Brady, Page, David B

Volltext

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice von Linch, Stefanie N., Kasiewicz, Melissa J., McNamara, Michael J., Hilgart-Martiszus, Ian F., Farhad, Mohammad, Redmond, William L.

Volltext

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA von Redmond, William L, Kasiewicz, Melissa J, Akporiaye, Emmanuel T

Volltext

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone von Graff, Julie N, Beer, Tomasz M, Alumkal, Joshi J, Slottke, Rachel E, Redmond, William L, Thomas, George V, Thompson, Reid F, Wood, Mary A, Koguchi, Yoshinobu, Chen, Yiyi, Latour, Emile, Bergan, Raymond C, Drake, Charles G, Moran, Amy E

Volltext

A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics von Iwamoto, Noriko, Koguchi, Yoshinobu, Yokoyama, Kotoko, Hamada, Akinobu, Yonezawa, Atsushi, Piening, Brian D, Tran, Eric, Fox, Bernard A, Redmond, William L, Shimada, Takashi

Volltext

Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity von Sturgill, Elizabeth R., Rolig, Annah S., Linch, Stefanie N., Mick, Courtney, Kasiewicz, Melissa J., Sun, Zhaoyu, Traber, Peter G., Shlevin, Harold, Redmond, William L.

Volltext

Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression von Redmond, William L, Triplett, Todd, Floyd, Kevin, Weinberg, Andrew D

Volltext

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor von Curti, Brendan D, Koguchi, Yoshinobu, Leidner, Rom S, Rolig, Annah S, Sturgill, Elizabeth R, Sun, Zhaoyu, Wu, Yaping, Rajamanickam, Venkatesh, Bernard, Brady, Hilgart-Martiszus, Ian, Fountain, Christopher B, Morris, George, Iwamoto, Noriko, Shimada, Takashi, Chang, ShuChing, Traber, Peter G, Zomer, Eliezer, Horton, J Rex, Shlevin, Harold, Redmond, William L

Volltext

A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy von Kim, Isaac, Rajamanickam, Venkatesh, Bernard, Brady, Chun, Brie, Wu, Yaping, Martel, Maritza, Sun, Zhaoyu, Redmond, William L., Sanchez, Katherine, Basho, Reva, McArthur, Heather, Page, David B.

Volltext

The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor von Crittenden, Marka R, Savage, Talicia, Cottam, Benjamin, Bahjat, Keith S, Redmond, William L, Bambina, Shelly, Kasiewicz, Melissa, Newell, Pippa, Jackson, Andrew M, Gough, Michael J

Volltext

OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor von GOUGH, Michael J, RUBY, Carl E, REDMOND, William L, DHUNGEL, Birat, BROWN, Alexis, WEINBERG, Andrew D

Volltext

Current Clinical Trial Landscape of OX40 Agonists von Yadav, Rashi, Redmond, William L.

Volltext

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab von Koguchi, Yoshinobu, Iwamoto, Noriko, Shimada, Takashi, Chang, Shu-Ching, Cha, John, Curti, Brendan D, Urba, Walter J, Piening, Brian D, Redmond, William L

Volltext

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer von Walker, Joshua M, Rolig, Annah S, Charych, Deborah H, Hoch, Ute, Kasiewicz, Melissa J, Rose, Daniel C, McNamara, Michael J, Hilgart-Martiszus, Ian F, Redmond, William L

Volltext

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer von Chun, Brie, Pucilowska, Joanna, Chang, ShuChing, Kim, Isaac, Nikitin, Benjamin, Koguchi, Yoshinobu, Redmond, William L, Bernard, Brady, Rajamanickam, Venkatesh, Polaske, Nathan, Fields, Paul A, Conrad, Valerie, Schmidt, Mark, Urba, Walter J, Conlin, Alison K, McArthur, Heather L, Page, David B

Volltext

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer von Graff, Julie N, Alumkal, Joshi J, Drake, Charles G, Thomas, George V, Redmond, William L, Farhad, Mohammad, Cetnar, Jeremy P, Ey, Frederick S, Bergan, Raymond C, Slottke, Rachel, Beer, Tomasz M

Volltext